DirectSens

DirectSens

Graz, Austria· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DirectSens is a private Austrian biotech firm commercializing a proprietary 3rd generation biosensor platform based on direct electron transfer (DET) enzymes. The company targets two primary markets: healthcare diagnostics (e.g., lactate monitoring) and food & beverage quality control (e.g., sugar analysis). With ISO-certified manufacturing and a decade of R&D, DirectSens positions itself as a provider of end-to-end biosensor solutions that offer oxygen-independent, mediator-free operation for improved reliability and ease of use.

Diagnostics

Technology Platform

3rd generation biosensor platform based on engineered enzymes capable of Direct Electron Transfer (DET), enabling oxygen-independent, mediator-free detection of analytes like sugars and lactate.

Opportunities

The growing demand for point-of-care and decentralized testing in healthcare creates a significant opportunity for DirectSens's easy-to-use, reliable biosensors.
In the food and beverage industry, the need for rapid, precise quality control during production aligns perfectly with the company's value proposition of simplifying analytical challenges.

Risk Factors

The company faces competition from large, established diagnostic firms and must prove the cost-benefit and performance superiority of its 3rd generation technology to drive adoption in conservative markets.
Scaling manufacturing and expanding its enzyme portfolio for new analytes are critical execution risks.

Competitive Landscape

DirectSens competes in the broad biosensor market against major players like Abbott, Roche, and Siemens in diagnostics, as well as numerous other biotechnology startups. Its key differentiation is its proprietary 3rd generation DET enzyme technology, which it positions as more reliable and simpler than mediator-dependent 2nd generation systems.